USGI Medical
13
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
15.4%
2 terminated/withdrawn out of 13 trials
77.8%
-8.7% vs industry average
0%
0 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Incisionless Suture Plications in a POSE2.0 Interventional Randomized Obesity Study
Role: lead
A Feasibility Study for the Treatment of Primary Obesity Cross-over Arm
Role: lead
A Feasibility Study for the Treatment of Primary Obesity
Role: lead
A Post-Market Surveillance Study of Using the g-Cath EZ for Treating Obesity
Role: lead
ESSENTIAL Trial™ Sham Cross-over
Role: lead
The USGI Medical ESSENTIAL Study for Weight Loss
Role: lead
Use of the Incisionless Operating Platform as a Primary Treatment for Obesity vs. Diet-Exercise Alone
Role: lead
ULTIMATE Study for Weight Loss
Role: lead
MOTIVATE Weight Loss Study
Role: lead
Gastric Restriction Using the EndoSurgical Operating System
Role: lead
NOTES-Assisted Laparoscopic Cholecystectomy Surgery
Role: lead
Endolumenal Gastric Pouch and Gastrojejunal Anastomosis Reduction
Role: lead
Endoscopic Stomach and Pouch Reduction in Patients With Weight Regain Following Roux-En-Y Bypass Surgery
Role: lead
All 13 trials loaded